These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27025318)

  • 41. Chemotherapy for metastatic castrate-sensitive prostate cancer.
    Miller RE; Sweeney CJ
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Words of wisdom: Re: Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials.
    Tombal B
    Eur Urol; 2014 May; 65(5):1013-4. PubMed ID: 24646499
    [No Abstract]   [Full Text] [Related]  

  • 43. [Development of new drugs for urological cancers].
    Akaza H
    Gan To Kagaku Ryoho; 1997 Oct; 24(13):1938-40. PubMed ID: 9350239
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Androgen deprivation before prostate radiotherapy: how long is long enough?
    Parker C
    Lancet Oncol; 2011 May; 12(5):411-2. PubMed ID: 21440506
    [No Abstract]   [Full Text] [Related]  

  • 45. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
    Vordos D; Paule B; Vacherot F; Allory Y; Salomon L; Hoznek A; Yiou R; Chopin D; Abbou CC; de la Taille A
    BJU Int; 2004 Sep; 94(4):524-7. PubMed ID: 15329105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
    Park JC; Eisenberger MA
    J Clin Oncol; 2016 Jan; 34(3):211-4. PubMed ID: 26628474
    [No Abstract]   [Full Text] [Related]  

  • 47. Intermittent androgen deprivation therapy in prostate cancer: is everything so clear?
    Mottet N
    Eur Urol; 2013 Jan; 63(1):121-2; discussion 123-4. PubMed ID: 22921963
    [No Abstract]   [Full Text] [Related]  

  • 48. [Chemotherapy of the hormone-refractory prostate cancer].
    Heine K; Wolff JM
    Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.
    Diamond E; Garcias Mdel C; Karir B; Tagawa ST
    Curr Treat Options Oncol; 2015 Feb; 16(2):9. PubMed ID: 25762124
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hormonal treatment for progression.
    Miller K
    Eur J Cancer; 2009 Sep; 45 Suppl 1():158-60. PubMed ID: 19775614
    [No Abstract]   [Full Text] [Related]  

  • 51. Re: A review of continuous vs intermittent androgen deprivation therapy: redefining the gold standard in the treatment of advanced prostate cancer. Myths, facts and new data on a ″perpetual dispute″.
    Mearini L
    Int Braz J Urol; 2014; 40(2):287-8. PubMed ID: 24856502
    [No Abstract]   [Full Text] [Related]  

  • 52. Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?
    Smith MR
    J Clin Oncol; 2008 Jun; 26(18):2932-3. PubMed ID: 18565878
    [No Abstract]   [Full Text] [Related]  

  • 53. Anti-androgens in treatment of prostate cancer.
    Waxman J; Pandha H
    Lancet; 1995 Oct; 346(8981):1030. PubMed ID: 7475556
    [No Abstract]   [Full Text] [Related]  

  • 54. Chemotherapy for patients with hormone-refractory prostate cancer.
    Joly F; Tannock IF
    Ann Oncol; 2004 Nov; 15(11):1582-4. PubMed ID: 15520057
    [No Abstract]   [Full Text] [Related]  

  • 55. Long- or short-term hormones for locally advanced prostate cancer?
    Brower V
    J Natl Cancer Inst; 2009 Dec; 101(23):1606-8. PubMed ID: 19910554
    [No Abstract]   [Full Text] [Related]  

  • 56. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
    Oncology (Williston Park); 1999 Jul; 13(7):1014. PubMed ID: 10442347
    [No Abstract]   [Full Text] [Related]  

  • 58. Metastatic castrate-resistant prostate cancer, dawn of a new age of management.
    Nemr EG
    BJU Int; 2013 Mar; 111(3):E9-E10. PubMed ID: 23444940
    [No Abstract]   [Full Text] [Related]  

  • 59. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
    Altundag K; Altundag O; Morandi P; Gunduz M
    Cancer; 2004 Sep; 101(5):1101-2; author reply 1102-3. PubMed ID: 15329924
    [No Abstract]   [Full Text] [Related]  

  • 60. Use of combined androgen blockade for advanced prostate cancer in British Columbia.
    Chau A; de Lemos ML; Pickles T; Blood P; Kovacic L; Abadi S; Barnett J
    J Oncol Pharm Pract; 2010 Jun; 16(2):121-6. PubMed ID: 19541764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.